Pieris Pharmaceuticals Reports Financial Results for the Third Quarter Ended September 30, 2017, and Provides Corporate Update
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
It is often only the minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bo…
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces its support for…
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that data on the…
. Zykadia® (ceritinib) is an approved treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose…
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics thro…
Veltassa® approved for marketing in the EU for hyperkalaemia First launches planned from the end of 2017 or early 2018 V…